Pulmonary Drug Delivery Systems Market Players:
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Lupin Limited
- Briggs Healthcare, Inc.
- Boehringer Ingelheim International GmbH
- Koninklijke Philips N.V.
- Merck & Co., Inc.
- 3M Company
- AstraZeneca PLC
- GSK plc
- GF Health Products, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of pulmonary drug delivery systems is assessed at USD 62.05 Billion.
The global pulmonary drug delivery systems market size was valued at over USD 59.33 Billion in 2025 and is expected to expand at a CAGR of around 5.1%, surpassing USD 97.57 Billion revenue by 2035.
The North America pulmonary drug delivery systems market is predicted to capture 45.2% share by 2035, fueled by rising prevalence of lung diseases and air pollution.
Key players in the market include Novartis AG, Lupin Limited, Briggs Healthcare, Inc., Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., Merck & Co., Inc., 3M Company, AstraZeneca PLC, GSK plc, GF Health Products, Inc.
